Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Neu, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neu, H. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1991) 27, 1-9
© 1991 The British Society for Antimicrobial Chemotherapy

research-article

The development of macrolides: clarithromycin in perspective

H. C. Neu

Departments of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University New York, NY, USA

Address for correspondence: Dr H. C. Neu, Department of Medicine, 630 West 168 Street, New York, NY 10032, USA

Macrolide antibiotics have been available and used clinically since 1952. The class of drugs originated from a soil sample obtained from the City of Ilo-Ilo on the Island of Paray in the Philippines. Erythromycin has been the most widely used agent of this class called ‘macrolides’ because they possess the macrocyclic lactone nucleus. Many esters of erythromycin are well established as agents to treat a variety of respiratory and cutaneous infections, particularly in children. There has been a resurgence of interest in macrolides as a result of the recognition of pathogens such as Legionella, Chlamydia and Campylobacter spp. A number of new 14-membered macrolides have been synthesised in recent years with the goal of overcoming some of the problems of the older erythromycin agents. There has been variable activity of erythromycin against Haemophilus influenzae; there has been gastrointestinal irritation, particularly in adults; and the older agents are administered four times a day. Clarithromycin has increased activity against Legionella, and Branhamella spp., and Pasteurella multocida, and, with its 14-OH metabolite, inhibits Haemophilus spp. It is also more active against chlamydia and against anaerobic species while retaining excellent activity against streptococci including Streptococcus pneumoniae. It has increased plasma peak levels and a sufficiently long half-life for twice daily administration. Furthermore, it is well tolerated. Thus clarithromycin offers potential for use in those areas in which a safe, well tolerated macrolide will be used, namely respiratory, skin structure and selected diarrhoeal and genital infections.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Fam MedHome page
K. H. Calhoun and J. A. Hokanson
Multicenter Comparison of Clarithromycin and Amoxicillin in the Treatment of Acute Maxillary Sinusitis
Arch Fam Med, August 1, 1993; 2(8): 837 - 840.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
J. B. Friedman
New Macrolide Antibiotics
Ann Intern Med, September 15, 1992; 117(6): 533 - 534.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
H. C. Neu
New Macrolide Antibiotics: Azithromycin and Clarithromycin
Ann Intern Med, March 15, 1992; 116(6): 517 - 519.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.